학술논문
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
Document Type
article
Author
I’ah Donovan-Banfield; Rebekah Penrice-Randal; Hannah Goldswain; Aleksandra M. Rzeszutek; Jack Pilgrim; Katie Bullock; Geoffrey Saunders; Josh Northey; Xiaofeng Dong; Yan Ryan; Helen Reynolds; Michelle Tetlow; Lauren E. Walker; Richard FitzGerald; Colin Hale; Rebecca Lyon; Christie Woods; Shazaad Ahmad; Dennis Hadjiyiannakis; Jimstan Periselneris; Emma Knox; Calley Middleton; Lara Lavelle-Langham; Victoria Shaw; William Greenhalf; Thomas Edwards; David G. Lalloo; Christopher J. Edwards; Alistair C. Darby; Miles W. Carroll; Gareth Griffiths; Saye H. Khoo; Julian A. Hiscox; Thomas Fletcher
Source
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
Molnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the antiviral efficacy of the drug against SARS-CoV-2. No treatment-associated SARS-CoV-2 mutations were identified.